Skip to main content

Table 3 Results of EGFR testing in selected centers in 2014a

From: NSCLC molecular testing in Central and Eastern European countries

 

EGFR, n (%)

Non-diagnostic

 

WT

Mut exon 18

Mut exon 19

Mut exon 20

Mut exon 21

Croatia (Zagreb)

561 (85.9)

8 (1.2)

46 (7)

8 (1.2)

30 (4.6)

11

Czech (Prague)

154 (90.6)

4 (2.4)

6 (3.5)

2 (1.2)

4 (2.2)

15

Czech (Hradec Kralove)

234 (90.0)

0

15 (5.8)

2 (0.8)

9 (3.5)

6

Hungary (Budapest, Timár)

350 (85.6)

4 (1.0)

22 (5.4)

14 (3.9)

19 (4.6)

57

Hungary (Budapest, Toth)

251 (93.3)

0

9 (3.3)

1 (0.4)

8 (3.1)

2

Hungary (Budapest, Kovalszky)

500 (88.5)

6 (1.1)

27 (4.8)

0

32 (5.7)

Hungary (Debrecen)

760 (89.6)

0

61 (7.2)

0

27 (3.2)

13

Hungary (Pécs)

112 (86.8)

0

10 (7.8)

0

7 (5.4)

Hungary (Szeged)

617 (92.6)

4 (0.6)

27 (4.1)

2 (0.3)

16 (2.4)

71

Slovakia

361 (87.6)

1 (0.2)

30 (7)

2 (0.5)

16 (3.8)

Slovenia

464 (86)

5 (0.9)

39 (7.2)

8 (1.5)

25 (4.6)

57

Turkey (Cerrahpaşa)

714 (87.9)

17 (2.1)

52 (6.4)

3 (0.4)

26 (3.2)

38

  1. EGFR epidermal growth factor receptor, WT wild-type
  2. aNote that these numbers cannot be compared directly because of the different criteria for selection of samples to test
  3. Exons 18 and 20 not tested